We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

37 hedge funds and large institutions have $70.8M invested in Sinovac Biotech, Ltd in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

9% more funds holding

Funds holding: 34 → 37 (+3)

8% less capital invested

Capital invested by funds: $77.1M → $70.8M (-$6.33M)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

Holders
37
Holders Change
+3
Holders Change %
+8.82%
% of All Funds
0.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
13
Closed
6
Calls
$119K
Puts
–
Net Calls
+$119K
Net Calls Change
-$6K

Top Buyers

Rank Fund Capital Flow
1
PRCM
Pine River Capital Management
Minnesota
+$2.22M
2
ACP
Acuta Capital Partners
California
+$812K
3
Renaissance Technologies
Renaissance Technologies
New York
+$377K
4
CS
Credit Suisse
Switzerland
+$370K
5
GP
GLG Partners
United Kingdom
+$354K

Top Sellers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
-$4.07M
2
Deutsche Bank
Deutsche Bank
Germany
-$432K
3
OTC
Opera Trading Capital
France
-$230K
4
VAM
Verity Asset Management
North Carolina
-$175K
5
GCP
GSA Capital Partners
United Kingdom
-$155K
Name Holding Trade Value Shares
Change 		Change in
Stake
KAM
26
Kassirer Asset Management
Ontario, Canada
$59K – – –
Walleye Trading
27
Walleye Trading
New York
$23K -$62.5K -10,200 -73%
AG
28
Advisor Group
Arizona
$23K +$23.9K +3,900 New
CG
29
Cutler Group
California
$17K -$13.5K -2,200 -43%
TRCT
30
Tower Research Capital (TRC)
New York
$14K -$3.57K -583 -20%
Wells Fargo
31
Wells Fargo
California
$7K -$919 -150 -11%
IA
32
IFP Advisors
Florida
$6K +$6.13K +1,000 New
Simplex Trading
33
Simplex Trading
Illinois
$4K +$4.29K +700 New
JP Morgan Chase
34
JP Morgan Chase
New York
$3K -$1.59K -259 -33%
Carson Wealth (CWM LLC)
35
Carson Wealth (CWM LLC)
Nebraska
$3K – – –
LTFS
36
Ladenburg Thalmann Financial Services
Florida
$3K – – –
UBS Group
37
UBS Group
Switzerland
$1K +$650 +106 New
OTC
38
Opera Trading Capital
France
– -$230K -36,146 Closed
VAM
39
Verity Asset Management
North Carolina
– -$175K -27,396 Closed
GCP
40
GSA Capital Partners
United Kingdom
– -$155K -24,200 Closed
VKH
41
Virtu KCG Holdings
New York
– -$113K -17,731 Closed
PP
42
PDT Partners
New York
– -$84K -13,084 Closed
AIG
43
American International Group
New York
– -$25K -3,900 Closed
1
2

SVA Hedge Fund Activity: Q2 2016 in Review

37 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2016, worth a combined $70.8M — down 8.2% from $77.1M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SVA positions and 6 closed out — a net gain of 3 holders — while 7 added to existing stakes and 13 trimmed.

The largest buyer was Pine River Capital Management, adding an estimated $2.22M. The largest seller was First Manhattan, cutting an estimated $4.07M.

  • 37 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2016, up from 34 in Q1 2016.
  • Funds reported $70.8M of Sinovac Biotech, Ltd stock for Q2 2016, down 8.2% quarter-over-quarter.
  • 9 funds opened new Sinovac Biotech, Ltd positions in Q2 2016 and 6 closed out, a net change of +3 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q2 2016 was Pine River Capital Management, an estimated $2.22M added.
  • The largest Sinovac Biotech, Ltd seller in Q2 2016 was First Manhattan, an estimated $4.07M sold.

Based on aggregated 13F filings for Q2 2016.